Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

被引：1075

作者：

Wells, Samuel A., Jr. ^{[1
]}

Robinson, Bruce G. ^{[2
]}

Gagel, Robert F. ^{[3
]}

Dralle, Henning ^{[4
]}

Fagin, James A. ^{[5
]}

Santoro, Massimo ^{[6
]}

Baudin, Eric ^{[7
]}

Elisei, Rossella ^{[8
]}

Jarzab, Barbara ^{[9
]}

Vasselli, James R.

Read, Jessica ^{[11
]}

Langmuir, Peter ^{[10
]}

Ryan, Anderson J. ^{[12
]}

Schlumberger, Martin J. ^{[7
]}

机构：

[1] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA

[2] Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Univ Halle Wittenberg, Halle, Germany

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Univ Naples Federico II, Naples, Italy

[7] Inst Gustave Roussy, Villejuif, France

[8] Univ Pisa, Pisa, Italy

[9] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland

[10] AstraZeneca, Wilmington, DE USA

[11] AstraZeneca, Macclesfield, Cheshire, England

[12] Univ Oxford, Oxford, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 02期

关键词：

ENDOCRINE NEOPLASIA SYNDROMES; RET PROTOONCOGENE; CARCINOMA; MUTATIONS; ZD6474; GUIDELINES; SURVIVAL; EFFICACY; THERAPY; KINASES;

D O I：

10.1200/JCO.2011.35.5040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC. Patients and Methods Patients with advanced MTC were randomly assigned in a 2: 1 ratio to receive vandetanib 300 mg/d or placebo. On objective disease progression, patients could elect to receive open-label vandetanib. The primary end point was progression-free survival (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments. Results Between December 2006 and November 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100). At data cutoff (July 2009; median follow-up, 24 months), 37% of patients had progressed and 15% had died. The study met its primary objective of PFS prolongation with vandetanib versus placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001). Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P < .001), and biochemical response (P < .001). Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65). A final survival analysis will take place when 50% of the patients have died. Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%). Conclusion Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761). J Clin Oncol 30:134-141. (C) 2011 by American Society of Clinical Oncology

引用

页码：134 / 141

页数：8

共 30 条

[21] Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis [J].

Rodriguez-Antona, Cristina ;

Pallares, Judith ;

Montero-Conde, Cristina ;

Inglada-Perez, Lucia ;

Castelblanco, Esmeralda ;

Landa, Inigo ;

Leskelae, Susanna ;

Leandro-Garcia, Luis J. ;

Lopez-Jimenez, Elena ;

Leton, Rocio ;

Cascon, Alberto ;

Lerma, Enrique ;

Carmen Martin, M. ;

Carmen Carralero, M. ;

Mauricio, Didac ;

Cruz Cigudosa, Juan ;

Matias-Guiu, Xavier ;

Robledo, Mercedes .

[22] Prognosis of medullary thyroid carcinoma - Demographic, clinical, and pathologic predictors of survival in 1252 cases [J].

Roman, Sanziana ;

Lin, Rong ;

Sosa, Julie Ann .

CANCER, 2006, 107 (09) :2134-2142

[23] Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer [J].

Santoro, M ;

Carlomagno, F .

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (01) :42-52

[24] Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer [J].

Schlumberger, Martin J. ;

Elisei, Rossella ;

Bastholt, Lars ;

Wirth, Lori J. ;

Martins, Renato G. ;

Locati, Laura D. ;

Jarzab, Barbara ;

Pacini, Furio ;

Daumerie, Chantal ;

Droz, Jean-Pierre ;

Eschenberg, Michael J. ;

Sun, Yu-Nien ;

Juan, Todd ;

Stepan, Daniel E. ;

Sherman, Steven I. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3794-3801

[25]

Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205

[26] ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma [J].

Vidal, M ;

Wells, S ;

Ryan, A ;

Cagan, R .

CANCER RESEARCH, 2005, 65 (09) :3538-3541

[27]

Wedge SR, 2002, CANCER RES, V62, P4645

[28]

WEIBULL W, 1951, J APPL MECH-T ASME, V18, P293

[29] Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer [J].

Wells, Samuel A., Jr. ;

Gosnell, Jessica E. ;

Gagel, Robert F. ;

Moley, Jeffrey ;

Pfister, David ;

Sosa, Julie A. ;

Skinner, Michael ;

Krebs, Annetta ;

Vasselli, James ;

Schlumberger, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) :767-772

[30] THE ANALYSIS OF RELAPSE CLINICAL-TRIALS, WITH APPLICATION TO A COMPARISON OF 2 ULCER TREATMENTS [J].

WHITEHEAD, J .

STATISTICS IN MEDICINE, 1989, 8 (12) :1439-1454

← 1 2 3 →